Candesartan for High Blood Pressure in Obesity
(END-RF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial will use chemicals and a drug called Candesartan to study how they affect certain receptors related to blood pressure. It focuses on obese individuals who often have high levels of a substance called ET-1, which is linked to high blood pressure. By blocking these receptors, the study aims to see if it can improve their function and help lower blood pressure in obese people. Candesartan has been studied extensively for its effects on blood pressure, particularly in hypertensive and obese patients.
Will I have to stop taking my current medications?
The trial requires that you stop taking medications that affect blood vessel function, like nitrates, and any blood thinners, such as aspirin.
Is Candesartan safe for humans?
How does the drug Candesartan differ from other treatments for high blood pressure in obesity?
Candesartan is unique because it blocks the angiotensin II receptor, which helps reduce blood pressure by relaxing blood vessels and decreasing the activity of the renin-angiotensin system, a key factor in obesity-related hypertension. This mechanism also offers potential benefits for improving insulin sensitivity and protecting organs like the heart and kidneys, which are often affected in obese individuals with high blood pressure.15678
What evidence supports the effectiveness of the drug Candesartan for treating high blood pressure in people with obesity?
Research suggests that drugs like Candesartan, which block the renin-angiotensin system, may be beneficial for treating high blood pressure in people with obesity. This is because they can help manage the increased activity of this system, which is often linked to obesity-related high blood pressure and other metabolic issues.1691011
Who Is on the Research Team?
Ryan Harris, PhD
Principal Investigator
Augusta University
Are You a Good Fit for This Trial?
This trial is for adults aged 18-40 who are dealing with high blood pressure and obesity. It's not open to those with cardiovascular, lung, kidney, liver, brain diseases or metabolic disorders; pregnant individuals; people on meds that affect blood vessels or anticoagulants like aspirin; those with anemia, postmenopausal women, or uncontrolled hypertension.Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Candesartan or placebo for 7 days to assess ETB receptor function
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Candesartan
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Augusta University
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator